Effect of bovine granulocyte colony-stimulating factor on the development of pneumonia caused by Mannheimia haemolytica.
The role of recruited neutrophils in Mannheimia haemolytica infection is controversial. We hypothesized that the neutrophilia induced by recombinant bovine granulocyte colony-stimulating factor (GCSF) would lead to rapid bacterial clearance and less severe lesions after infection with M. haemolytica. Two experiments (A and B) were conducted in which four calves per experiment were treated daily with 5 microg/kg GCSF and four calves per experiment were treated with saline. All 16 calves were challenged with 5 x 10(9) colony-forming units (cfu)/ml (experiment A) or 4.5 x 10(8) cfu/ml (experiment B) of M. haemolytica bacteria, into the right bronchus by bronchoscope-placed catheter. The mean maximal blood neutrophil counts in non-GCSF-treated and GCSF-treated calves before bacterial challenge were 5.6 +/- 0.7 x 10(9)/liter and 25.4 +/- 2.7 x 10(9)/liter, respectively. Two untreated calves became neutropenic and were euthanatized 2 days after infection because of severe respiratory distress. GCSF-treated calves had a 37% reduction in lung lesions compared with nontreated calves, and this difference was significant (P=0.04) when the effect of previous antibody titre to leukotoxin was considered. The effect of GCSF treatment on the severity of clinical signs seemed to be influenced by the antibody titre to M. haemolytica leukotoxin, although this effect could not be conclusively addressed. In conclusion, GCSF induced neutrophilia and partially protected calves against experimental infection with M. haemolytica. These results imply that increased numbers of neutrophils may, under some circumstances, protect against severe pneumonia caused by M. haemolytica.
Youssef
S A
SA
Department of Pathobiology, University of Guelph, Guelph, Ontario N1G 2W, Canada.
Clark
M E
ME
Caswell
J L
JL
D000818:Animals; D002417:Cattle; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D008168:Lung / Q000473:pathology; D008297:Male; D016978:Mannheimia haemolytica / Q000472:pathogenicity*; D009503:Neutropenia / Q000188:drug therapy; D009504:Neutrophils / Q000187:drug effects; D012766:Pasteurellosis, Pneumonic / Q000188:drug therapy* / Q000276:immunology
D016179:Granulocyte Colony-Stimulating Factor